Essential for health.
Harnessed for medicine.
The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting microbiome disruption can increase susceptibility to immune disorders, infections, neurological conditions, cancer, and other serious conditions. New therapeutics that deliver beneficial microbial communities hold the promise of transforming patient outcomes in a wide range of therapeutic areas with serious unmet patient needs.
Finch has established a leading portfolio of microbiome assets designed with insights from human microbiota transplantation studies. These studies involve the transfer of microbiota from healthy individuals to individuals with disease, an area of intense research with hundreds of third-party clinical studies spanning dozens of different conditions.
In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets.
CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent CDI
Pre-clinical microbiome assets designed to target ulcerative colitis (FIN-524), Crohn’s disease (FIN-525), and autism spectrum disorder (FIN-211)
Robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents
An industry leading IP estate
In collaboration with microbiome pioneers such as Dr. Thomas Borody, founder of the Centre for Digestive Diseases in Australia, Finch has established a leading patent portfolio with significant longevity and critical relevance for the microbiome field.
- >70 issued U.S. and foreign patents and >140 patent applications pending
- Robust protection for CP101 into 2036
in the field
- Priority dates of foundational patent family predate the industry, enabling broad protection for composition of matter, methods of use, manufacture, and formulation claims into 2031
Broad & diverse
- Protection for multiple microbiome product strategies, including donor-derived and donor-independent product strategies
- Diverse therapeutic coverage, with protection for a wide range of indications of interest